Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2024)

Barinthus Biotherapeutics' (BRNS) quarterly Net Margin came in at 54.31% in Q3 2024, up 99.24% on a QoQ basis from 7132.93% in Q2 2023.

Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2024) Analysis & Trends

Barinthus Biotherapeutics (BRNS) has 5 years of Net Margin data on file, last reported at 54.31% in Q3 2024.

Quarterly Net Margin changed N/A year-over-year to 54.31% in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 443.97% (down 3524.0% YoY) and the FY2024 annual result came in at 408.73%, up 874925.0% from the prior year.
Net Margin grew to 54.31% in Q3 2024, from 7132.93% in the prior quarter.
In the past five years, Net Margin ranged from a high of 1681900.0% in Q4 2021 to a low of 48162.86% in Q2 2021.
A 5-year average of 105077.97% and a median of 670.07% in 2020 frame the typical range for Net Margin.
Annual changes were most pronounced in 2021 — Net Margin surged 168553418 bps — and 2022, when it tumbled 168222775 bps.
Tracing BRNS's Net Margin over 5 years: stood at 3634.18% in 2020, then surged by 46380 bps to 1681900.0% in 2021, then tumbled by 100 bps to 327.75% in 2022, then slumped by 2076 bps to 7132.93% in 2023, then jumped by 99 bps to 54.31% in 2024.
The last three Net Margin figures came in at 54.31% (Q3 2024), 7132.93% (Q2 2023), and 3893.8% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Barinthus Biotherapeutics	25.01 Mn	25.01 Mn	-	-

Download Data